Two COVID-19 Oral Drugs Conditionally Approved by China

Two innovative Chinese oral anti-SARS-CoV-2 drugs, Xiannuoxin (simnotrelvir/ritonavir) and VV116 (deuremidevir hydrobromide), were conditionally approved for marketing by China’s National Medical Products Administration (NMPA) in late January after urgent review and approval under the Special Examination and Approval of Drugs Policy.

Both drugs are intended for the treatment of adult patients infected with mild to moderate COVID-19 and should be used strictly under doctors’ instructions.

COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.

‘The Xiannuoxin and VV116, oral small-molecule drugs developed to treat mild to moderate COVID-19 adult patients.’

Tweet it Now

Xiannuoxin is the first 3CL- targeted (3-chymotrypsin-like protease, 3CLpro), an innovative anti-SARS-CoV-2 drug with intellectual property rights in China. It was jointly developed by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences (CAS), the Wuhan Institute of Virology (WIV) of CAS, and Simcere Pharmaceutical Group Limited.

Oral small molecule Xiannuoxin targets 3CL protease, which is essential for SARS-CoV-2 virus replication. The combination of low-dose ritonavir with simnotrelvir helps to slow the breakdown of Xiannuoxin in the body to improve the antiviral effect.

Two Chinese Anti COVID-19 Drugs Conditionally Approved for Marketing

Preclinical animal research indicated that Xiannuoxin showed potent, broad-spectrum anti-SARS-CoV-2 activity with no genotoxicity observed. Multiple clinical studies in China evaluated the efficacy and safety of Xiannuoxin and met the pre-specified primary efficacy endpoint. The study comprised 1,208 adult patients with symptomatic mild to moderate COVID-19.

Results of the study demonstrated that Xiannuoxin is safe and effective for adult patients infected with mild to moderate COVID-19 and has extensive clinical value.

Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.

VV116 non-covalently binds to the active center of RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp (RNA dependent and RNA polymerase) of the virus and blocking viral replication, thus realizing an antiviral effect.

Preclinical studies have demonstrated that VV116 exhibits significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, showing no genetic toxicity.

Omicron Variant of COVID-19
Omicron variant is a mutated strain of coronavirus (SARS-CoV-2) with faster transmissibility and enhanced virulence compared to the original COVID-19 virus.

Results showed that among the 1,277 study participants, the time from first administration to the sustained resolution of clinical symptoms for the VV116 group was significantly shorter in comparison with the placebo group, and the change in viral load from baseline, as well as other virological indicators for the VV116 group, were better than the placebo group.

The marketing of Xiannuoxin and VV116 is expected to provide patients in China with more effective COVID-19 treatment options.

COVID-19 Vaccine: Myths and Facts
Debunking several misconceptions or myths that have surfaced regarding covid vaccination is important and focus on the facts related to COVID-19 vaccines.

Source-Eurekalert